Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 93Stomach Neoplasms 56Rectal Neoplasms 51Colonic Neoplasms 47Pancreatic Neoplasms 21Neoplasms 14Carcinoma, Hepatocellular 14Neoplasm Metastasis 13Adenocarcinoma 10Parkinson Disease 4, Autosomal Dominant Lewy Body 9Lymphoma, Large B-Cell, Diffuse 9Cholangiocarcinoma 8Adenocarcinoma Of Esophagus 8Esophageal Neoplasms 5Biliary Tract Neoplasms 5Neurotoxicity Syndromes 4Esophageal Squamous Cell Carcinoma 4Lymphoma, Extranodal NK-T-Cell 3Gastrointestinal Neoplasms 3Gallbladder Neoplasms 3Peritoneal Neoplasms 2Lymphoma 2Liver Neoplasms 2Hepatoblastoma 2Gastrointestinal Diseases 2Colorectal Adenocarcinoma 2Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Spinocerebellar Degenerations 1

Interventions

xaliproden 2Polyamines 1Oxaliplatin 1Leucovorin 1Fluorouracil 12,2'-dithiodiethanesulfonic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Paresthesia × Oxaliplatin × Clear all
NCT00305188 2016-05-04

Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.

Sanofi

Phase 3 Completed
879 enrolled
Gastrointestinal

Neoplasm Metastasis, Paresthesia, Colorectal Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡